PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00407576
Recruitment Status : Completed
First Posted : December 5, 2006
Last Update Posted : July 2, 2017
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:
Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Healthy Drug: [11C]MeS-IMPY Phase 1

Detailed Description:
Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in brain. A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration. There are multiple binding sites available on beta-amyloid plaques. Three clearly identified sites are Congo-red type, Thioflavin-T type, and FDDNP type. Radioligands currently under development using positron emission tomography (PET) for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site, such as [11C]PIB and [11C]SB-13. Though variously effective, these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities. Therefore, we have recently developed [11C]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more accurate quantification of amyloid plaques in AD brain. In the current protocol, we wish to evaluate [11C]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients.

Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Primary Purpose: Treatment
Official Title: PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
Study Start Date : December 1, 2006
Actual Primary Completion Date : November 7, 2008

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.

Informed Consent.

AD Patients: Mini-Mental State Examination (score greater than or equal to 10).

AD Patients: Meet NINCDS-ADRDA criteria for probable AD.


  1. Current or prior history of any alcohol or drug abuse.
  2. Severe systemic disease based on history and physical exam.
  3. Positive result on urine screen for illicit drugs.
  4. Laboratory tests with clinically significant abnormalities.
  5. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
  6. Pregnancy or breast feeding.
  7. Claustrophobia.
  8. Presence of ferromagnetic metal in the body or heart pacemaker.
  9. History of brain disease other than Alzheimer's disease.
  10. Unable to lay on one's back for the PET/MRI scan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00407576

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Mental Health (NIMH)

Responsible Party: Robert B. Innis, M.D./National Institute of Mental Health, National Institutes of Health Identifier: NCT00407576     History of Changes
Other Study ID Numbers: 070036
First Posted: December 5, 2006    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: November 7, 2008

Keywords provided by National Institutes of Health Clinical Center (CC):
Alzheimer's Disease
Positron Emission Tomography
Beta-Amyloid Plaques
Alzheimer Disease
Healthy Volunteer

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders